Maine datamining law suit statement

3 December 2007

Three major health information companies (IMS Health, Versipan and Wolters Kluwer Health) have issued a joint statement concerning the preliminary injunction hearing on a state law (Maine LD-4) that would prevent the gathering of prescribing information from health care professionals for "drug marketing purposes" (Marketletter December 3). The court case in the northeastern state of Maine follows a recent victory by the firms against a similar law in neighboring New Hampshire (Marketletters passim).

The joint statement declares: "we simply believe that the Maine statute is not good health care policy. The key to improving health care quality, and reducing costs and variability in treatment is access to more information - not less. Provider-level prescription data is a critical resource in this information flow for all stakeholders."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight